



METHYLPHENIDATE HYDROCHLORIDE IR



Rubió 55
years

We are pharmacypathfinders

The first line treatment for Attention Deficit Hyperactivity Disorder (ADHD)



General Information

Name:	Rubifen®
API:	Methylphenidate Hydrochloride
Formulation:	Immediate Release (IR)
Main Presentation:	Box containing 30 tablets of 5/10/20 mg. Other presentations are also available.

Indications

- Treatment for children (over 6 years old) and adolescents with Attention Deficit Hyperactivity Disorder (ADHD).

Characteristics

- IR enables very flexible dosage adjustments for picky eater patients, slow growth patients and to avoid insomnia.
- Economical treatment option.
- Over 25 years of clinical experience guarantee Rubifen® as a safe product.
- Therapeutic effect within the first hour after intake with a duration of 4 hours.
- Initial Dosage: One or two intakes per day.
- Lactose, gluten, egg and latex free.

Registration and Marketing Authorization

- First Methylphenidate Hydrochloride launched in Spain (1983) with own Trademark Rubifen®.
- CTD dossier available with Bioequivalence (BE) conducted in 1999 for the EU MRP in 2003.
- Available new e-CTD Dossier with new BE from Q1 2014. Registration in new countries as Generic of Ritalin® (IR), preferable as First Generic.
- Rubifen® is the top international-sale product of Rubió, marketed already in several countries such as AD, AR, BE, CL, DE, NL, DK, GT, IL, IR, LK, NI, NO, DO PA, PT, NZ, MT, TH, SE, SG, UK, UY, ZA and with future launch in MX.

Deal Design

- We are looking for Distributors and/or Licensing Partners having a relevant sales structure in Central Nervous System (CNS) diseases to do a proper promotion of Rubifen® brand name or with a long sales expertise in the Generic Business to market it as a generic of Ritalin®.
- Deal design consisting of a Supply & Distribution and/or Licensing Agreement to market the Finished Product manufactured by Laboratorios Rubió, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió

For 55 years Laboratorios Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partner- Strategy

Laboratorios Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubió has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
Fax: +34 937 721 602
www.laboratoriosrubio.com

Contact:

export@labrubio.com